No Data
No Data
Buy Rating Affirmed for Mural Oncology on Strong Potential of Nemvaleukin Therapy and Upcoming Milestones
Mural Oncology's Investor Day Highlights Cancer Treatment Trials
Express News | Mural Oncology To Host Virtual Investor Day, Provide New Clinical Insight Into Trial Design, Statistical Assumptions, And Progress Of Late-stage Trials Of Nemvaleukin
Mural Oncology Provides Update on ARTISTRY-7 at Investor Day
Mural Oncology Provides Update on ARTISTRY-6 Cohort 2 at Investor Day
Mural Oncology Plans to Nominate Candidate for IL-18 Program by Year-end